A Randomized Trial of PCSK9 Inhibitors in the Treatment of Calcific Aortic Stenosis
Status:
NOT_YET_RECRUITING
Trial end date:
2029-01-31
Target enrollment:
Participant gender:
Summary
Calcific aortic stenosis (CAS) can cause severe adverse cardiac events, but there are currently no effective drugs that can prevent or delay the progression of the disease. Our trial aims to investigate the effect of PCSK9 inhibitors on preventing or delaying the progression of CAS.
Phase:
PHASE3
Details
Lead Sponsor:
Beijing Anzhen Hospital
Collaborators:
Beijing Hospital Beijing Jishuitan Hospital Chinese Academy of Medical Sciences, Fuwai Hospital Nanchong Central Hospital Peking University First Hospital